Nephrogenous cyclic AMP, adenylate cyclase-stimulating activity, and the humoral hypercalcemia of malignancy.

[1]  A. C. Webb,et al.  Messenger ribonucleic acid from tumors associated with humoral hypercalcemia of malignancy directs the synthesis of a secretory parathyroid hormone-like peptide. , 1985, Endocrinology.

[2]  G. Mundy,et al.  Tumor products and the hypercalcemia of malignancy. , 1985, The Journal of clinical investigation.

[3]  R. Baron,et al.  Squamous carcinoma model of humoral hypercalcemia of malignancy. , 1984, Endocrinology.

[4]  M. J. Moore,et al.  The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. , 1984, The New England journal of medicine.

[5]  R. Baron,et al.  Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy. , 1984, Endocrinology.

[6]  Gideon,et al.  Factors associated with humoral hypercalcemia of malignancy stimulate adenylate cyclase in osteoblastic cells. , 1983, The Journal of clinical investigation.

[7]  G. Mundy,et al.  Absence of parathyroid hormone messenger RNA in nonparathyroid tumors associated with hypercalcemia. , 1983, The New England journal of medicine.

[8]  A. F. Stewart,et al.  Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphate dehydrogenase-stimulating activity in extracts of tumors from patients with humoral hypercalcemia of malignancy. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Strewler,et al.  Human renal carcinoma cells produce hypercalcemia in the nude mouse and a novel protein recognized by parathyroid hormone receptors. , 1983, The Journal of clinical investigation.

[10]  R. Baron,et al.  Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. , 1982, The Journal of clinical endocrinology and metabolism.

[11]  A. Broadus,et al.  Hypercalcemia associated with gynecologic malignancies: Biochemical characterization , 1982, Cancer.

[12]  S. Tuma,et al.  Radioimmunoassay for the middle region of human parathyroid hormone using an homologous antiserum with a carboxy-terminal fragment of bovine parathyroid hormone as radioligand. , 1982, The Journal of clinical endocrinology and metabolism.

[13]  A. F. Stewart,et al.  Malignancy-associated hypercalcemia: evaluation with a cytochemical bioassay for parathyroid hormone. , 1981, The Journal of clinical endocrinology and metabolism.

[14]  O. Clark,et al.  Endogenous biologically active human parathyroid hormone: measurement by a guanyl nucleotide-amplified renal adenylate cyclase assay. , 1981, The Journal of clinical endocrinology and metabolism.

[15]  F. Singer,et al.  Urinary and nephrogenous adenosine 3',5'-monophosphate in the hypercalcemia of malignancy. , 1981, The Journal of clinical endocrinology and metabolism.

[16]  A. F. Stewart,et al.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. , 1980, The New England journal of medicine.

[17]  H. Wahner,et al.  Scintigraphic evaluation of the skeleton in multiple myeloma. , 1980, Mayo Clinic proceedings.

[18]  Patricia A. Johnson,et al.  Elevated nephrogenous cyclic AMP with normal serum parathyroid hormone levels in patients with lung cancer. , 1980, The Journal of clinical endocrinology and metabolism.

[19]  E. Siris,et al.  Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. , 1980, The New England journal of medicine.

[20]  R. Bockman,et al.  Comparison of commercially available parathyroid hormone immunoassays in the differential diagnosis of hypercalcemia due to primary hyperparathyroidism or malignancy. , 1979, Annals of internal medicine.

[21]  R. Coombes,et al.  Calcium metabolism in cancer. Studies using calcium isotopes and immunoassays for parathyroid hormone and calcitonin , 1976, Cancer.

[22]  J. Habener,et al.  Parathyroid hormone secretion in vivo. Demonstration of a calcium-independent nonsuppressible component of secretion. , 1976, The Journal of clinical investigation.

[23]  B. Riggs,et al.  Radioimmunoassay of parathyroid hormone in hypercalcemic patients with malignant disease. , 1974, The American journal of medicine.

[24]  J. Nelson,et al.  The chloride-phosphate ratio in hypercalcemia. , 1974, Annals of internal medicine.

[25]  J. Potts,et al.  Nonparathyroid humoral hypercalcemia in patients with neoplastic diseases. , 1973, The New England journal of medicine.

[26]  T. Nemoto,et al.  Phosphaturia in hypercalcemic breast cancer patients. , 1972, The Journal of clinical endocrinology and metabolism.

[27]  B. Riggs,et al.  Immunologic differentiation of primary hyperparathyroidism from hyperparathyroidism due to nonparathyroid cancer. , 1971, The Journal of clinical investigation.

[28]  K. Kivirikko,et al.  Modifications of a specific assay for hydroxyproline in urine. , 1967, Analytical biochemistry.

[29]  H. O. Heinemann.  Metabolic alkalosis in patients with hypercalcemia. , 1965, Metabolism: clinical and experimental.

[30]  A. F. Stewart,et al.  Elevations in circulating 1,25-dihydroxyvitamin D in three patients with lymphoma-associated hypercalcemia. , 1985, The Journal of clinical endocrinology and metabolism.

[31]  E. Frenkel,et al.  Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. , 1984, Annals of internal medicine.

[32]  R. Horst,et al.  A microassay for 1,25-dihydroxyvitamin D not requiring high performance liquid chromatography: application to clinical studies. , 1984, The Journal of clinical endocrinology and metabolism.

[33]  A. Broadus.  Nephrogenous cyclic AMP. , 1981, Recent progress in hormone research.